18,090 Shares in Cencora, Inc. (NYSE:COR) Bought by World Investment Advisors LLC

World Investment Advisors LLC acquired a new stake in shares of Cencora, Inc. (NYSE:COR) in the 3rd quarter, Holdings Channel.com reports. The fund acquired 18,090 shares of the company’s stock, valued at approximately $4,072,000.

A number of other hedge funds have also recently modified their holdings of COR. New Millennium Group LLC purchased a new position in Cencora during the second quarter valued at $26,000. MFA Wealth Advisors LLC purchased a new stake in shares of Cencora in the second quarter worth $30,000. Concord Wealth Partners bought a new position in shares of Cencora during the third quarter valued at $30,000. SYSTM Wealth Solutions LLC purchased a new position in shares of Cencora in the 2nd quarter worth about $36,000. Finally, Ashton Thomas Securities LLC bought a new position in Cencora in the 3rd quarter worth about $41,000. Institutional investors own 97.52% of the company’s stock.

Insiders Place Their Bets

In other news, Chairman Steven H. Collis sold 21,509 shares of the stock in a transaction that occurred on Tuesday, October 22nd. The shares were sold at an average price of $235.80, for a total value of $5,071,822.20. Following the transaction, the chairman now owns 285,088 shares in the company, valued at $67,223,750.40. This represents a 7.02 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Over the last three months, insiders have sold 93,018 shares of company stock valued at $22,478,942. Insiders own 15.80% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have weighed in on COR shares. Bank of America restated a “neutral” rating and set a $245.00 price objective (down from $275.00) on shares of Cencora in a research note on Wednesday, September 18th. Robert W. Baird raised their price target on shares of Cencora from $287.00 to $292.00 and gave the company an “outperform” rating in a research report on Thursday, November 7th. StockNews.com cut Cencora from a “strong-buy” rating to a “buy” rating in a research report on Friday, September 20th. Wells Fargo & Company reduced their target price on Cencora from $249.00 to $237.00 and set an “equal weight” rating for the company in a report on Friday. Finally, Barclays boosted their price target on Cencora from $263.00 to $290.00 and gave the stock an “overweight” rating in a research note on Thursday, November 7th. Two research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $275.60.

Cencora Price Performance

NYSE COR opened at $232.24 on Friday. The stock has a market capitalization of $44.89 billion, a price-to-earnings ratio of 30.92, a PEG ratio of 1.54 and a beta of 0.45. Cencora, Inc. has a 1-year low of $195.83 and a 1-year high of $253.27. The company has a debt-to-equity ratio of 4.84, a current ratio of 0.88 and a quick ratio of 0.53. The business’s fifty day moving average price is $238.36 and its 200-day moving average price is $233.91.

Cencora Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, November 29th. Shareholders of record on Friday, November 15th were given a $0.55 dividend. This represents a $2.20 annualized dividend and a yield of 0.95%. This is a boost from Cencora’s previous quarterly dividend of $0.51. The ex-dividend date of this dividend was Friday, November 15th. Cencora’s dividend payout ratio (DPR) is presently 29.29%.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.